{"abstract":"The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Stage One Immunotherapeutics, Inc., incorporated in Delaware and with headquarters in Pennsylvania.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2025/10/02/2025-19199.html","cfr_references":[],"citation":"90 FR 47782","comment_url":null,"comments_close_on":"2025-10-17","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Center for Advancing Translational Sciences' Office of Strategic Alliances on or before October 17, 2025 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2025-19199","effective_on":null,"end_page":47783,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2025/10/02/2025-19199.xml","html_url":"https://www.federalregister.gov/documents/2025/10/02/2025-19199/prospective-grant-of-an-exclusive-patent-license-substituted-quinoline-analogs-as-aldehyde","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2025-19199?publication_date=2025-10-02","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2025-10-02/2025-19199/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":65,"last_updated":"2026-06-24 08:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-10-02/pdf/2025-19199.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-19199.pdf?1759322711","publication_date":"2025-10-02","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2025/10/02/2025-19199.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":47782,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Substituted Quinoline Analogs As Aldehyde Dehydrogenase 1A1 Inhibitors","toc_doc":"Substituted Quinoline Analogs as Aldehyde Dehydrogenase 1A1 Inhibitors","toc_subject":"Licenses; Exemptions, Applications, Amendments, etc.","topics":[],"type":"Notice","volume":90}